BusinessTeneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific AntibodiesBy Nasdaq OMXJan 8, 2018, 1:00 PM UTC
BusinessTeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of HematologyBy Nasdaq OMXDec 11, 2017, 1:00 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessCrown Bioscience Announces Collaboration to Develop Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) AntibodyBy Nasdaq OMXMay 8, 2017, 2:04 PM UTC
BusinessTeneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
BusinessXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital HyperinsulinismBy Nasdaq OMXOct 19, 2016, 1:01 PM UTC
